BORDEAUX MDS WINTER SCHOOL FOR YOUNG
|
|
- Britton Griffin
- 6 years ago
- Views:
Transcription
1 BORDEAUX MDS WINTER SCHOOL FOR YOUNG NEUROLOGISTS INFUSION THERAPIES IN PARKINSON S DISEASE Apomorphine, T. Henriksen Tove Henriksen, MD MDS Clinic University Hospital of Bispebjerg, Copenhagen
2 MOTOR FLUCTUATIONS Levodopacarbidopa intestinal gel (LCIG) Erratic gastric emptying Bloating Late on No on Hyperkinesias T Henriksen, PD Unit Apomorphine DBS
3 Duodenal carbidopa/ levodopa gel infusion Device aided treatments Advanced treatment Complex treatment CDS CDD Deep brain stimulation Subcutaneous apomorphine infusion
4 INSUFFICIENT EVIDENCE FROM HEAD-TO- HEAD COMPARISONS Small study of four patients showed Improved off rating for levodopa versus apomorphine Improved quality of life for levodopa versus apomorphine according to PDQ-39 BUT the authors of a systematic review concluded: Clinical judgement remains the only tool to determine whether DBS, apomorphine infusion or levodopa infusion would be of benefit to a particular patient with advanced PD and complex motor symptoms Where possible, patient preference should form a significant part of the decision-making process Nyholm D, et al. Acta Neurol Scand 2009;119:345-8.Clarke CE, et al. Parkinsonism Relat Disord. 2009;15:
5 ALGORITHM FOR THE SELECTION OF PATIENTS WHO ARE CANDIDATES FOR CDS TREATMENTS Age <65 70 years with prominent motor fluctuations and moderate dyskinesia STN-DBS Subcutaneous apomorphine Levodopa/carbidopa duodenal infusion Cancer or similar Severe dementia GI problems Age <65 70 years with very severe dyskinesia (no therapeutic window) Parkinson s disease age >65 70 years STN-DBS Levodopa/carbidopa duodenal infusion Fluctuations ± dyskinesia Subcutaneous apomorphine Levodopa/carbidopa duodenal infusion Modified, Antonini A, Tolosa E. Expert Rev Neurother. 2009;9: Reproduced with permission of Expert Review Ltd.
6 6
7 DUODENAL CARBIDOPA/LEVODOPA GEL INFUSION (DUODOPA ) Stable plasma concentrations of l-dopa attenuate severe On-off fluctuations in advanced PD (Shoulson 1975) i.v. trials large infusion volume, irritation of veins 1990s SM Aquilonius University of Uppsala
8 CARBIDOPA/LEVODOPA GEL INFUSION THERAPY Levodopa/carbidopa (2 g/day) in gel suspension 100 ml cassette (2000 mg) PEG with intestinal tube Ambulatory pump Mono therapy Morning bolus dose Continuous maintenance infusion over 16 hr
9 Change in Hours From Baseline to Week P = P = P =.3294 LCIG LC-IR P =.0015 "Off" Time Primary Endpoint "On" Time Without Troublesome Dyskinesia Key Secondary Endpoint SECONDARY EFFICACY: PD SYMPTOM DIARY ANALYSIS "On" Time Without Dyskinesia "On"Time With Nontroublesome Dyskinesia P =.8574 "On" Time With Troublesome Dyskinesia LCIG, levodopa-carbidopa intestinal gel; LC- IR,immediate-release levodopa-carbidopa. Olanow et al., (2014) Lancet Neurol,
10 LCIG (n = 35) LC-IR (n = 31) Treatment Difference (95% CI) SECONDARY EFFICACY: QOL/CAREGIVER BURDEN P Value PDQ-39 summary index 10.9 (3.3) 3.9 (3.2) 7.0 ( 12.6 to 1.4).0155 Mean CGI-I score at final assessment 2.3 (0.4) 3.0 (0.4) 0.7 ( 1.4 to 0.1).0258 UPDRS part II b 1.8 (1.3) 1.3 (1.3) 3.0 ( 5.3 to 0.8).0086 UPDRS part III b 1.5 (2.4) 2.9 (2.4) 1.4 ( 2.8 to 5.6).5020 EQ-5D 0.05 (0.04) 0.02 (0.04) 0.07 ( 0.01 to 0.15).0670 Zarit Burden Interview 2.8 (3.7) 1.7 (3.3) 4.5 ( 10.7 to 1.7).1501 Levodopa total daily dose, mg 91.7 (96.6) (94.9) ( to 8.5).0625 Overall mean (SD) levodopa rescue dose, mg (20.3) (21.9 ) 40.8 ( to 18.8).1762 Patients treated with LCIG showed significant improvement (compared with patients receiving standard oral LC-IR) in the activities of daily living subscale of the UPDRS (part II) and measures of QoL 10 Data are the least squares mean change from baseline to week 12 (SE) unless otherwise stated. CGI-I, Clinical Global Impression Improvement; EQ-5D, EuroQol quality-of-life-5 Dimensions; LCIG, levodopa-carbidopa intestinal gel; LC-IR, immediate-release levodopa-carbidopa; PDQ-39, Parkinson Disease Questionnaire-39 items; QoL, quality of life; UPDRS, Unified Parkinson s Disease Rating Scale. a For CGI-I, 1 is very much improved, 2 is much improved, 3 is minimally improved, 4 is no change, 5 is minimally worse, 6 is much worse, and 7 is very much worse. b UPDRS was completed in the on state. Olanow CW, et al. (2014) Lancet Neurol,
11 4 prospective, multicenter studies Safety data Already published 412 patients 911 days observation (range ) 2017, T Henriksen
12 Patients With Treatment-Emergent Adverse Events, % SAFETY: AES AND DEVICE COMPLICATIONS OVER TIME Complication of device insertion Abdominal pain Procedural pain Constipation Nausea Flatulence Orthostatic hypotension Weeks 12 AE, adverse event. Olanow CW, et al. (2014) Lancet Neurol,
13 2017, T Henriksen
14 SUBCUTANEOUS APOMORPHINE INFUSION 1988 A Lees Stibe
15 Researches into the Constitution of the Opium Bases. On the Action of Hydrochloric Acid on Codeia. Matthiessen A, C. R. A. Wright. Proceedings of the Royal Soci.of London, Vol.18,1869, pp Schwab RS et al. Apomorphine in Parkinson s disease. Trans Am Neurol Assoc 1951 High hepatic first pass metabolism and poor oral bioavailability. Short duration Peripheral dopaminergic adverse effects: Nausea, postural hypotension, prerenal azotemia Apomorphine, T. Henriksen Domperidone (Agid, Lancet 1979), peripherally acting dopamine antagonist
16 1960S Non-ergoline dopamine agonist (D2, D3, D4, D1) Apomorphine: Improvement in tremor and rigidity (Schwab 1951, Trans Am Neurol Ass) Oral mg/day reduced on-off (Cotzias 1970, NEJM Catecholaminergic compound common to dopamine No opioid analgesic properties Short-acting potent agonist with effect on D 1 and D 2 receptors Latency to motor response 10 minutes Duration of action of a single injection 60 minutes Apomorphine, T. Henriksen
17 ROUTES OF ADMINISTRATION Per orally First pass effect Intravenous infusion Intra vascular thrombosis, crystals (3 of 6 patients) Sublingual New gel formulation on the way Intranasal spray Disabling nasal irritation Inhaled (Grosset KA et al 2013), rescue off A randomized, double-blind, 2:1 active: placebo, parallelgroup, 55 patients dose range 1.5 to 4.5 mg, significantly improved UPDRS 3 aborted a greater proportion of off periods at-home, compared to placebo. However, daily off time was not significantly reduced by the use of inhaled apomorphine Apomorphine, T. Henriksen
18 Ruiz PJG et al, Movement Disorders 2008 Apomorphine, T. Henriksen
19 Apomorphine, T. Henriksen From 148 adverse events collected: 93 (62.8%) were mild 44 (29.7%) moderate 11 (7.4%) severe, but did not lead to treatment dropout. No case of HA was reported in these 82 long-term-treated patients. MOVEMENT DISORDERS 2008
20 Apomorphine, T. Henriksen
21 2017, T Henriksen
22 STUDY DESIGN, 107 PATIENTS, 23 CENTRES 2017, T Henriksen
23 MOTOR STATUS BY PARKINSON DIARY 2017, T Henriksen
24 PATIENT GLOBAL IMPRESSION CHANGE FROM BASELINE TO WEEK , T Henriksen
25 SIDE EFFECTS 2017, T Henriksen
26 WHEN? Apomorphine, T. Henriksen
27 Psychosocial impact of Parkinson s disease: Employment Method: survival analysis of employment Approx. 450 patients with onset of disease <65 y Loss of employment (including retirement) on average 4.9 years after Parkinson s disease onset: Parkinson s disease onset <45 y: 6.7 y Parkinson s disease onset >56 y: 1.7 y In young patients: Loss of professional career opportunities Greater economic impact of unemployment Schrag A, Banks P. Time of loss of employment in Parkinson's disease. Mov Disord 2006; 21: Copyright (2006 Movement Disorder Society); Reproduced with permission of John Wiley & Sons, Inc.
28 WHY NOT EARLIER? LCIG Price Polyneuropathy Weight Apomorphine Nodules Price DBS Early Stim Disease duration 7.5 y, fluctuations 1.5 y, same improvement of QoL as 14 y disease duration. Are the patients ready? No, last resort (interview study, Sperens 2017) Change of IPG Risk of infection Apomorphine, T. Henriksen
29 CONCLUSION Main indication for advanced therapy: Motor fluctuations +/- dyskinesias in spite of optimized peroral/transdermal PD therapy. Non-motor symptoms can be part of the indication. Due to contraindications for DBS, large groups of patients are only suitable for pump therapy A special out patient set up with a PD nurse specialist Factors influencing the choice of advanced therapy: methodology and practical aspects, as well as, expected effects on motor- and non-motor symptoms Start thinking about advanced therapy already in the early complications phase of advanced Parkinson s disease
BORDEAUX MDS WINTER SCHOOL FOR YOUNG
BORDEAUX MDS WINTER SCHOOL FOR YOUNG NEUROLOGISTS HOW TO EVALUATE MOTOR COMPLICATIONS IN PARKINSON'S DISEASE T. Henriksen Tove Henriksen, MD MDS Clinic University Hospital of Bispebjerg, Copenhagen MOTOR
More informationIndividual Study Table Referring to Part of Dossier: Volume: Page:
Synopsis Abbott Laboratories Name of Study Drug: DUODOPA Intestinal Gel Name of Active Ingredient: Levodopa-carbidopa Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority
More informationAdvanced Therapies for Motor Symptoms in PD. Matthew Boyce MD
Advanced Therapies for Motor Symptoms in PD Matthew Boyce MD Medtronic Education Teva Speakers Bureau Acadia Speakers Bureau Disclosures Discuss issues in advanced PD Adjunct therapies to levo-dopa Newer
More informationContinuous dopaminergic stimulation
Continuous dopaminergic stimulation Angelo Antonini Milan, Italy GPSRC CNS 172 173 0709 RTG 1 As PD progresses patient mobility becomes increasingly dependent on bioavailability of peripheral levodopa
More informationApomorphine for the treatment of refractory motor fluctuations in late stage Parkinson's disease : an old drug revisited
Pérez Lloret, Santiago Apomorphine for the treatment of refractory motor fluctuations in late stage Parkinson's disease : an old drug revisited Preprint del documento publicado en European Journal of Neurology,
More informationSummary of Report Results
Summary of Report Results Abbott Laboratories Name of Study Drug: DUODOPA Intestinal Gel Name of Active Ingredient: Levodopa-Carbidopa Individual Study Table Referring to Part of Dossier: Volume: Page:
More informationCOMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP Policy agreed by (Vale of York CCG/date)
COMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP Policy agreed by (Vale of York CCG/date) Drug, Treatment, Device name Co-careldopa 2000mg/500mg intestinal gel (Duodopa, Solvay Pharmaceuticals)
More informationRe-Submission. Scottish Medicines Consortium. rasagiline 1mg tablet (Azilect ) (No. 255/06) Lundbeck Ltd / Teva Pharmaceuticals Ltd.
Scottish Medicines Consortium Re-Submission rasagiline 1mg tablet (Azilect ) (No. 255/06) Lundbeck Ltd / Teva Pharmaceuticals Ltd 10 November 2006 The Scottish Medicines Consortium (SMC) has completed
More informationWelcome and Introductions
Parkinson s Disease Spotlight on Treatment Advances Tuesday, January 26, 2016 Welcome and Introductions Stephanie Paul Vice President Development and Marketing American Parkinson Disease Association 1
More informationWelcome and Introductions
Parkinson s Disease Spotlight on Addressing Motor and Non-Motor Symptoms The Changing Landscape Wednesday, March 8, 2017 Welcome and Introductions Stephanie Paul Vice President Development and Marketing
More informationThe Shaking Palsy of 1817
The Shaking Palsy of 1817 A Treatment Update on Parkinson s Disease Dr Eitzaz Sadiq Neurologist CH Baragwanath Acadamic Hospital Parkinson s Disease O Premature death of dopaminergic neurons O Symptoms
More informationClinical Commissioning Policy: Levodopa-Carbidopa Intestinal Gel (LCIG)
Clinical Commissioning Policy: Levodopa-Carbidopa Intestinal Gel (LCIG) Reference: NHS England D04/P/e NHS England INFORMATION READER BOX Directorate Medical Commissioning Operations Patients and Information
More informationUpdate in the Management of Parkinson s Disease
Update in the Management of Parkinson s Disease What s standard? What s new? What s coming? Bruno V. Gallo, M.D. Assistant Professor of Neurology, FIU Wertheim College of Medicine Director, Parkinson &
More informationWHAT DEFINES YOPD? HANDLING UNIQUE CONCERNS REBECCA GILBERT, MD, PHD VICE PRESIDENT, CHIEF SCIENTIFIC OFFICER, APDA MARCH 14, 2019
WHAT DEFINES YOPD? HANDLING UNIQUE CONCERNS REBECCA GILBERT, MD, PHD VICE PRESIDENT, CHIEF SCIENTIFIC OFFICER, APDA MARCH 14, 2019 YOUNG ONSET PARKINSON S DISEASE Definition: Parkinson s disease diagnosed
More informationMedication Management & Strategies When the levodopa honeymoon is over
Medication Management & Strategies When the levodopa honeymoon is over Eric J Pappert, MD Parkinson s Disease & Movement Disorders Center Neurology Associates Medication Options in Parkinson s Carbidopa/Levodopa
More informationMotor Fluctuations Stephen Grill, MD, PHD Parkinson s and Movement Disorders Center of Maryland and Johns Hopkins University
Motor Fluctuations Stephen Grill, MD, PHD Parkinson s and Movement Disorders Center of Maryland and Johns Hopkins University I have no financial interest with any entity producing marketing, re-selling,
More information10th Medicine Review Course st July Prakash Kumar
10th Medicine Review Course 2018 21 st July 2018 Drug Therapy for Parkinson's disease Prakash Kumar National Neuroscience Institute Singapore General Hospital Sengkang General Hospital Singhealth Duke-NUS
More information2.0 Synopsis. Levodopa-Carbidopa Intestinal Gel M Clinical Study Report R&D/15/1285. (For National Authority Use Only)
2.0 Synopsis AbbVie Inc. Name of Study Drug: Levodopa Carbidopa Intestinal Gel (LCIG) Name of Active Ingredient: Levodopa-Carbidopa Individual Study Table Referring to Part of Dossier: Volume: Page: (For
More informationAPOMORPHINE OLD DRUG ; NEW LIFE?
APOMORPHINE OLD DRUG ; NEW LIFE? Dr Susan H Fox MRCP (UK), PhD Professor Neurology, University of Toronto Movement Disorders Clinic, Toronto Western Hospital CNSF, Halifax June 25 th 2018 DISCLOSURES Nature
More informationTreatment of Parkinson s Disease: Present and Future
Treatment of Parkinson s Disease: Present and Future Karen Blindauer, MD Professor of Neurology Director of Movement Disorders Program Medical College of Wisconsin Neuropathology: Loss of Dopamine- Producing
More informationSurgical Management of Parkinson s Disease
Surgical Management of Parkinson s Disease Shyamal H. Mehta MD, PhD Assistant Professor of Neurology, Movement Disorders Division Mayo Clinic College of Medicine Mayo Clinic, Arizona 2016 MFMER slide-1
More informationCommunicating About OFF Episodes With Your Doctor
Communicating About OFF Episodes With Your Doctor Early in Parkinson s disease (PD), treatment with levodopa and other anti-pd drugs provides continuous benefit. As the disease progresses, however, symptom
More informationScottish Medicines Consortium
Scottish Medicines Consortium rotigotine 2mg/24 hours, 4mg/24 hours, 6mg/24 hours, 8mg/24 hours transdermal patch (Neupro ) (No: 289/06) Schwarz Pharma Ltd. 7 July 2006 The Scottish Medicines Consortium
More informationMedications used to treat Parkinson s disease
Medications used to treat Parkinson s disease Edwin B. George, M.D., Ph.D. Director of Wayne State University Movement Disorder Clinic University Health Center Neurology Clinic University Health The John
More informationAnticholinergics. COMT* Inhibitors. Dopaminergic Agents. Dopamine Agonists. Combination Product
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-945-5220 Fax 503-947-1119 Class Update: Parkinson s Drugs Month/Year of Review:
More informationLiterature Scan: Anti-Parkinson s Agents
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationhome environments of patients
A mobile-based system can assess Parkinson s disease symptoms from home environments of patients Treatment of Parkinson s disease involves major challenges like the large within- and between-patient variability
More informationDeep Brain Stimulation: Patient selection
Deep Brain Stimulation: Patient selection Halim Fadil, MD Movement Disorders Neurologist Kane Hall Barry Neurology Bedford/Keller, TX 1991: Thalamic (Vim) DBS for tremor Benabid AL, et al. Lancet. 1991;337(8738):403-406.
More informationParkinson s Disease Update. Presented by Joanna O Leary, MD Movement disorder neurologist Providence St. Vincent s
Parkinson s Disease Update Presented by Joanna O Leary, MD Movement disorder neurologist Providence St. Vincent s What is a movement disorder? Neurological disorders that affect ability to move by causing
More informationParkinson s Disease. Gillian Sare
Parkinson s Disease Gillian Sare Outline Reminder about PD Parkinson s disease in the inpatient Surgical patients with PD Patients who cannot swallow End of life care Parkinson s disease PD is the second
More informationEvidence compendium. Research study summaries supporting the use of Medtronic deep brain stimulation (DBS) for Parkinson s disease
Evidence compendium Research study summaries supporting the use of Medtronic deep brain stimulation (DBS) for Parkinson s disease CONTENTS Introduction... 4 Index of study summaries... 6 Parkinson s disease
More informationContinuous dopaminergic stimulation in a patient treated with daytime Levodopa-carbidopa intestinal gel and overnight Rotigotine: a case report
Acta Biomed 2017; Vol. 88, N. 2: 190-195 DOI: 10.23750/abm.v88i2.5038 Mattioli 1885 Case report Continuous dopaminergic stimulation in a patient treated with daytime Levodopa-carbidopa intestinal gel and
More informationEffective Shared Care Agreement for the treatment of severe motor complications in people with Parkinson Disease with apomorphine (APO-go )
Effective Shared Care Agreement for the treatment of severe motor complications in people with Parkinson Disease with apomorphine (APO-go ) This shared care agreement outlines the ways in which the responsibilities
More informationCONTINUOUS THERAPY BECAUSE LIFE GOESON
CONTINUOUS THERAPY BECAUSE LIFE GOESON Investigating the effectiveness and safety of ND0612, an investigational medicine for patients with advanced Parkinson s Disease New medication limited by Federal
More informationCENTENE PHARMACY AND THERAPEUTICS NEW DRUG REVIEW 3Q17 July August
BRAND NAME Xadago GENERIC NAME Safinamide MANUFACTURER Newron Pharmaceuticals SpA holds license; granted approval. US WorldMeds, LLC exclusive licensee and distributor in the U.S. DATE OF APPROVAL March
More informationLevodopa/carbidopa intestinal gel, Quality of life, Well-being, Advanced Parkinson s disease, Caregivers.
1.0 Abstract Title Study On Patient- And Caregiver-Reported Symptoms And Outcomes With Levodopa/Carbidopa Intestinal Gel For The Treatment Of Advanced Parkinson s Disease. ADEQUA Study. Keywords Levodopa/carbidopa
More informationPD: Key Treatment Considerations
PD: Key Treatment Considerations 2018 Management of Neurologic and Neurosurgical Disorders in Daily Practice Elise Anderson MD Medical Co-Director, PBSI Movement Disorders 11/27/2018 1 Outline Treatment
More informationClinical Study Impact of Duodopa on Quality of Life in Advanced Parkinson s Disease: A UK Case Series
Parkinson s Disease Volume 2013, Article ID 362908, 5 pages http://dx.doi.org/10.1155/2013/362908 Clinical Study Impact of Duodopa on Quality of Life in Advanced Parkinson s Disease: A UK Case Series T.
More informationLet s Look at Parkinson s (PD) Sheena Morgan Parkinson s Disease Nurse Specialist Isle of Wight NHS Trust November 2016
Let s Look at Parkinson s (PD) Sheena Morgan Parkinson s Disease Nurse Specialist Isle of Wight NHS Trust November 2016 What is Parkinson s? Parkinson's is a progressive neurological condition. People
More informationDr Barry Snow. Neurologist Auckland District Health Board
Dr Barry Snow Neurologist Auckland District Health Board Dystonia and Parkinson s disease Barry Snow Gowers 1888: Tetanoid chorea Dystonia a movement disorder characterized by sustained or intermittent
More informationUpdate on Parkinson s disease and other Movement Disorders October 2018
Update on Parkinson s disease and other Movement Disorders October 2018 DR. JONATHAN EVANS CONSULTANT IN NEUROLOGY QUEEN S MEDICAL CENTRE NOTTINGHAM Disclosures: Honoraria UCB, Britannia, Allergan, AbbVie
More informationBest Medical Treatments for Parkinson s disease
Best Medical Treatments for Parkinson s disease Bernadette Schöneburg, M.D. June 20 th, 2015 What is Parkinson s Disease (PD)? Progressive neurologic disorder that results from the loss of specific cells
More informationProgram Highlights. Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone Medical Center New York, New York
Program Highlights David Swope, MD Associate Professor of Neurology Mount Sinai Health System New York, New York Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone
More informationDuodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease
Articles CME VIDEO Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease D. Nyholm, MD, PhD; A.I.M. Nilsson Remahl, MD, PhD; N. Dizdar, MD, PhD; R. Constantinescu, MD;
More informationPD ExpertBriefings: Parkinson s Medications: Today and Tomorrow Led By: Cynthia L. Comella, M.D., F.A.A.N.
PD ExpertBriefings: Parkinson s Medications: Today and Tomorrow Led By: Cynthia L. Comella, M.D., F.A.A.N. To hear the session live on: Tuesday, April 17, 2012 at 1:00 PM ET. DIAL: 1 (888) 272-8710 and
More informationFaculty. Joseph Friedman, MD
Faculty Claire Henchcliffe, MD, DPhil Associate Professor of Neurology Weill Cornell Medical College Associate Attending Neurologist New York-Presbyterian Hospital Director of the Parkinson s Institute
More informationParkinson s Disease medications
Parkinson s Disease medications In correlation to the Unified Parkinson s disease rating scale Ayaan Mohamed Degree Thesis in Pharmacy 15 ECTS Bachelor s Level Report passed: Spring 2017 Supervisor: Miles
More informationMotor Fluctuations in Parkinson s Disease
Motor Fluctuations in Parkinson s Disease Saeed Bohlega, MD, FRCPC Senior Distinguished Consultant Department of Neurosciences King Faisal Specialist Hospital & Research Centre Outline Type of fluctuations
More informationAnnouncing FDA Approval of GOCOVRI TM
Announcing FDA Approval of GOCOVRI TM August 24, 2017 2017 Adamas Pharmaceuticals, Inc. All Rights Reserved. 1 Forward-looking Statements Statements contained in this presentation regarding expected future
More informationRasagiline and Rapid Symptomatic Motor Effect in Parkinson s Disease: Review of Literature
Neurol Ther (2014) 3:41 66 DOI 10.1007/s40120-013-0014-1 REVIEW Rasagiline and Rapid Symptomatic Motor Effect in Parkinson s Disease: Review of Literature Michele Pistacchi Francesco Martinello Manuela
More informationContinuous therapy. Because life goes ON. Jefferies Global Healthcare Conference June, 2016
Continuous therapy. Because life goes ON Jefferies Global Healthcare Conference June, 2016 21 1 Disclaimer These slides and the accompanying oral presentation contain forward-looking statements concerning
More informationClinical Trial Results Posting
RD..3.2 V1. Page/Seite 1 of/von 5 CT Registry ID#: NCT2428 (ClinicalTrials.gov Identifier number) These results are supplied for informational purposes only. Prescribing decisions should be made based
More information35 th Annual J.P. Morgan Healthcare Conference
35 th Annual J.P. Morgan Healthcare Conference Forward Looking Statement This presentation includes forward-looking statements. All statements, other than statements of historical facts, regarding management's
More informationParkinson's Disease KP Update
Parkinson's Disease KP Update Andrew Imbus, PA-C Neurology, Movement Disorders Kaiser Permanente, Los Angeles Medical Center No disclosures "I often say now I don't have any choice whether or not I have
More informationAnnex I. Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s)
Annex I Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s) 1 Scientific conclusions Taking into account the PRAC Assessment Report on the PSUR(s) for carbidopa
More informationParkinson s Disease in 60 minutes. Dr. Claire Hinnell Movement Disorder Neurologist Director Movement Disorder Clinic JPOCSC
Parkinson s Disease in 60 minutes Dr. Claire Hinnell Movement Disorder Neurologist Director Movement Disorder Clinic JPOCSC S Plan of attack S What causes Parkinson s disease brief S Symptoms/Diagnostic
More informationOverview of Parkinson s disease Research at University of Colorado
Overview of Parkinson s disease Research at University of Colorado Brian D. Berman, MD, MS May 12, 2018 University of Colorado Movement Disorders Center Terminology Basic science pure/fundamental scientific
More informationPARKINSON S DISEASE. Nigrostriatal Dopaminergic Neurons 5/11/16 CARDINAL FEATURES OF PARKINSON S DISEASE. Parkinson s disease
5/11/16 PARKINSON S DISEASE Parkinson s disease Prevalence increases with age (starts 40s60s) Seen in all ethnic groups, M:F about 1.5:1 Second most common neurodegenerative disease Genetics role greater
More informationAPOMORPHINE (Adults) Shared Care Guidelines DRUG:
Shared Care Guidelines DRUG: APOMORPHINE (Adults) Indication: Treatment of motor fluctuations in patients with Parkinson's disease which is not sufficiently controlled by oral anti-parkinson medication.
More informationContinuous therapy. Because life goes ON. Jefferies 2015 Global Healthcare Conference June, 2015
Continuous therapy. Because life goes ON Jefferies 2015 Global Healthcare Conference June, 2015 21 1 Disclaimer These slides and the accompanying oral presentation contain forward-looking statements concerning
More informationARE YOUR LEVODOPA PILLS WORKING LIKE THEY USED TO?
ARE YOUR LEVODOPA PILLS WORKING LIKE THEY USED TO? You may have noticed a change... Levodopa is a common treatment for Parkinson s, and doctors have relied on it for decades. Over time as Parkinson s progresses,
More informationDeep Brain Stimulation for Parkinson s Disease & Essential Tremor
Deep Brain Stimulation for Parkinson s Disease & Essential Tremor Albert Fenoy, MD Assistant Professor University of Texas at Houston, Health Science Center Current US Approvals Essential Tremor and Parkinsonian
More informationKey Concepts and Issues in Parkinson s Disease in 2016
Key Concepts and Issues in Parkinson s Disease in 2016 Michael Rezak, M.D., Ph.D. Section Chief, Neurosciences Institute Director, Movement Disorders and Neurodegenerative Diseases Center Northwestern
More informationTRANSPARENCY COMMITTEE OPINION. 18 March 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 March 2009 REQUIP LP 2 mg extended-release tablet Box of 21 tablets (CIP: 379 214-8) Box of 28 tablets (CIP: 379
More informationSafinamide: un farmaco innovativo con un duplice meccanismo d azione
Safinamide: un farmaco innovativo con un duplice meccanismo d azione AINAT Sardegna Cagliari, 26 novembre 2016 Carlo Cattaneo Corporate Medical Advisor CNS & Rare Diseases Reichmann H. et al., European
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationRotigotine patches (Neupro) in early Parkinson s disease Edited by AdRes Health Economics & Outcomes Research
Rotigotine patches (Neupro) in early Parkinson s disease Edited by AdRes Health Economics & Outcomes Research Synthetic DRUG PROFILE Introduction Parkinson s disease (PD) is a neurodegenerative disorder
More informationOptimizing levodopa therapy for Parkinson s disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective
EXPERT OPINION Optimizing levodopa therapy for Parkinson s disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective David J Brooks Division of Neuroscience, Faculty
More informationparts of the gastrointenstinal tract. At the end of April 2008, it was temporarily withdrawn from the US Market because of problems related to
parts of the gastrointenstinal tract. At the end of April 2008, it was temporarily withdrawn from the US Market because of problems related to crystallization of the drug, which caused unreliable drug
More informationPatient selection for surgery: Parkinson s disease
Patient selection for surgery: Parkinson s disease Dr. María C. Rodríguez-Oroz Neurology and Neuroscience. University Hospital Donostia, Research Institute BioDonostia, Ikerbasque Senior Researcher San
More informationBasal ganglia motor circuit
Parkinson s Disease Basal ganglia motor circuit 1 Direct pathway (gas pedal) 2 Indirect pathway (brake) To release or augment the tonic inhibition of GPi on thalamus Direct pathway There is a tonic inhibition
More informationOptimizing Clinical Communication in Parkinson s Disease:
Optimizing Clinical Communication in Parkinson s Disease:,Strategies for improving communication between you and your neurologist PFNCA Symposium March 25, 2017 Pritha Ghosh, MD Assistant Professor of
More informationREFERENCE CODE GDHC391DFR PUBLICAT ION DATE M ARCH 2014 DUODOPA (PARKINSON S DISEASE) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC391DFR PUBLICAT ION DATE M ARCH 2014 DUODOPA (PARKINSON S DISEASE) - Executive Summary The table below provides a summary of the key metrics for Duodopa in the 8MM Parkinson s Disease
More informationSPOTLIGHT ON MOVEMENT FUNCTION: COPING WITH ON/OFF PERIODS WELCOME AND INTRODUCTIONS
PARKINSON S DISEASE SPOTLIGHT ON MOVEMENT FUNCTION: COPING WITH ON/OFF PERIODS THURSDAY, MAY 11, 2017 WELCOME AND INTRODUCTIONS Stephanie Paul Vice President Development and Marketing American Parkinson
More informationPa t h w a y s. Pa r k i n s o n s. MacMahon D.G. Thomas S. Fletcher P. Lee M. 2006
Pathways bolt 16/6/06 20:38 Page 1 Pa t h w a y s A PARADIGM FOR DISEASE MANAGEMENT IN Pa r k i n s o n s Disease MacMahon D.G. Thomas S. Fletcher P. Lee M. 2006 Clinical diagnosis Pa r k i n s o n s disease
More informationMusculoskeletal Problems Affect the Quality of Life of Patients with Parkinson s Disease
https://doi.org/10.14802/jmd.18022 / J Mov Disord 2018;11(3):133-138 pissn 2005-940X / eissn 2093-4939 ORIGINAL ARTICLE Musculoskeletal Problems Affect the Quality of Life of Patients with Parkinson s
More informationAcute management of in-patient Parkinson s Disease patients
Acute management of in-patient Parkinson s Disease patients Contents Pages Introduction and Admission advice 2 Nil by Mouth Guidance 3 5 Complex therapy advice (Apomorphine, DBS, Duodopa) 6 Surgical peri-operative
More informationWhat s new for diagnosing and treating Parkinson s Disease?
What s new for diagnosing and treating Parkinson s Disease? Erika Driver-Dunckley, MD Associate Professor of Neurology Program Director Movement Disorders Fellowship Assistant Program Director Neurology
More informationOpicapone is a peripheral, selective and reversible catechol-o-methyltransferase (COMT) inhibitor 1.
New Medicines Committee Briefing June 2017 Opicapone (Ongentys ) as adjunctive therapy in adult patients with Parkinson s disease and end-of-dose motor fluctuations Opicapone (Ongentys ) is to be reviewed
More informationREFERENCE CODE GDHC237CFR PUBLICAT ION DATE M ARCH 2014 PARKINSON S DISEASE - JAPAN DRUG FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC237CFR PUBLICAT ION DATE M ARCH 2014 PARKINSON S DISEASE - JAPAN DRUG FORECAST AND MARKET ANALYSIS TO 2022 Executive Summary Sales for Parkinson s Disease in Japan Market The Parkinson
More information05-Nov-15. Impact of Parkinson s Disease in Australia. The Nature of Parkinson s disease 21st Century
Peter Silburn Professor Clinical Neuroscience University of Queensland Queensland Brain Institute Neurosciences Queensland Impact of in Australia Second most common neurodegenerative disorder Up to 64,000
More informationS H A R E D C A R E G U I D E L I N E Drug: Apomorphine Indication Parkinson s Disease
S H A R E D C A R E G U I D E L I N E Drug: Apomorphine Indication Parkinson s Disease Introduction Indication: Treatment of Parkinson s Disease with Apomorphine Background: Patients with Parkinson s disease
More informationShared Care Agreement Apomorphine For use in Parkinson s Disease
Shared Care Agreement Apomorphine For use in Parkinson s Disease This shared care agreement outlines suggested ways in which the prescribing responsibilities can be shared between the specialist and GP.
More informationCommonly encountered medications and their side effects - what the generalist needs to know
Commonly encountered medications and their side effects - what the generalist needs to know Jeremy Cosgrove Consultant Neurologist Leeds Teaching Hospitals NHS Trust Outline: Parkinson s medications and
More informationScott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE
Scott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE LEARNING OBJECTIVES The Course Participant will: 1. Be familiar with the pathogenesis of Parkinson s Disease (PD) 2. Understand clinical
More informationREFERENCE CODE GDHC235CFR PUBLICAT ION DATE M ARCH 2014 PARKINSON S DISEASE - US DRUG FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC235CFR PUBLICAT ION DATE M ARCH 2014 PARKINSON S DISEASE - US DRUG FORECAST AND MARKET ANALYSIS TO 2022 Sales for Parkinson s Disease in the US The Parkinson s disease market in the
More informationThe Use of Amantadine HCL in Clinical Practice: A Study of Old and New Indications
The Use of Amantadine HCL in Clinical Practice: A Study of Old and New Indications Carlos Singer, MD* Spiridon Papapetropoulos, MD, PhD* Gadith Uzcategui, BA Lydia Vela, MD * Department of Neurology, University
More information10/13/2017. Disclosures. Deep Brain Stimulation in the Treatment of Movement Disorders. Deep Brain Stimulation: Objectives.
Deep Brain Stimulation in the Treatment of Movement Disorders Disclosures None Eleanor K Orehek, M.D. Movement Disorders Specialist Noran Neurological Clinic 1 2 Objectives To provide an overview of deep
More informationAnand R, 1 Borgohain R, 2 Stocchi F, 3 Giuliani R, 4 Rice P, 5 Forrest E, 4 Lucini V, 4 for the Study 016/018 Investigators IL, USA
First 2-year, placebo-controlled study in Parkinson s disease patients with motor fluctuations indicates safinamide may benefit patients with more severe dyskinesia Anand R, 1 Borgohain R, 2 Stocchi F,
More informationACUTE MANAGEMENT OF PARKINSON S PATIENTS WHO ARE NIL BY MOUTH (NBM) OR WHO HAVE A COMPROMISED SWALLOW NHS LANARKSHIRE PARKINSON S TEAM
ACUTE MANAGEMENT OF PARKINSON S PATIENTS WHO ARE NIL BY MOUTH (NBM) OR WHO HAVE A COMPROMISED SWALLOW NHS LANARKSHIRE PARKINSON S TEAM 1 CONTENTS: TOPIC PAGE Introduction 3 What should you do when a PD
More informationCADTH Canadian Drug Expert Committee Recommendation
CADTH COMMON DRUG REVIEW CADTH Canadian Drug Expert Committee Recommendation (Final) APOMORPHINE HYDROCHLORIDE (MOVAPO PALADIN LABS INC.) Indication: Parkinson s disease RECOMMENDATION: The CADTH Canadian
More informationParkinson Disease. Lorraine Kalia, MD, PhD, FRCPC. Presented by: Ontario s Geriatric Steering Committee
Parkinson Disease Lorraine Kalia, MD, PhD, FRCPC Key Learnings Parkinson Disease (L. Kalia) Key Learnings Parkinson disease is the most common but not the only cause of parkinsonism Parkinson disease is
More informationIs Safinamide Effective as an Add-on Medication in Treating Parkinson's Disease Motor Symptoms?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2016 Is Safinamide Effective as an Add-on
More informationSponsor Novartis. Generic Drug Name AFQ056. Therapeutic Area of Trial L-dopa induced dyskinesias in Parkinson s disease (PD-LID)
Sponsor Novartis Generic Drug Name AFQ056 Therapeutic Area of Trial L-dopa induced dyskinesias in Parkinson s disease (PD-LID) Approved Indication Investigational Protocol Number CAFQ056A2223 Title 13-week,
More informationNovel approaches to the pharmacological treatment of Parkinson s disease. Peter Jenner King s College UK
Novel approaches to the pharmacological treatment of Parkinson s disease Peter Jenner King s College UK Disclosures and Disclaimers Speakers fees and consultancy fees have been received from Britannia
More informationREFERENCE CODE GDHC395DFR PUBLICAT ION DATE M ARCH 2014 APOKYN (PARKINSON S DISEASE) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC395DFR PUBLICAT ION DATE M ARCH 2014 APOKYN (PARKINSON S DISEASE) - Executive Summary The table below provides a summary of the key metrics for Apokyn in the 8MM Parkinson s Disease
More informationOCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA
OMED 17 OCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA 29.5 Category 1-A CME credits anticipated ACOFP / AOA s 122 nd Annual Osteopathic Medical Conference & Exposition Joint Session with ACOFP and Cleveland
More informationEMERGING TREATMENTS FOR PARKINSON S DISEASE
EMERGING TREATMENTS FOR PARKINSON S DISEASE Katerina Markopoulou, MD, PhD Director Neurodegenerative Diseases Program Department of Neurology NorthShore University HealthSystem Clinical Assistant Professor
More informationSwitching from pergolide to pramipexole in patients with Parkinson s disease
J Neural Transm (2001) Switching 108: 63 70 from pergolide to pramipexole in PD 63 Switching from pergolide to pramipexole in patients with Parkinson s disease P. A. Hanna 1,2, L. Ratkos 2, W. G. Ondo
More information